Sirnaomics Completes the Preclinical Study of STP125G for Treating Cardiovascular Diseases
Shots:
- Sirnaomics has completed the preclinical study of STP125G assessing its safety & efficacy in non-human primate (NHP) models to support IND submission for conducting P-I trial in cardiovascular disease indications
- In the study (N=4), STP125G showed dose-dependent silencing at 1mg/kg, 3mg/kg & 10mg/kg, with max. efficacy at 10mg/kg at wk.4 that remained for another 9wks. Safety was favorable at SC dosing of 50mg/kg, 100mg/kg & 250mg/kg, with similar silencing efficacy to 10mg/kg
- STP125G is a second siRNA therapy that targets ApoC3 mRNA and is developed using Sirnaomics’ GalAhead mxRNA technology for treating cardiovascular diseases
Ref: Sirnaomics | Image: Sirnaomics
Related News:- Sirnaomics Reports the Completion Patient Dosing of STP707 in P-I Study for Treatment of Multiple Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
